PDL BioPharma Inc. (NASDAQ:PDLI) went up by 1.98% during the previous trading session, and it is maintaining the win ahead of Monday’s trading session. The share price of the Biotechnology giant went up by $3.09 to trade ended Monday trading at $3.03. This is up from the $3.03 price recorded on Friday’s trading session. Thanks to this latest performance, PDLI is closer to the higher price 52-week target of $2.49 and further from the lowest price target of $2.49. Its performance from the start of the year has also been positive, with PDLI up by 14.71% year-to-date.
PDL BioPharma Inc. (PDLI) started the day trading at $3.04 and recorded an intraday high of $3.13. It also recorded an intraday low of $2.95 during Monday’s trading session. PDL BioPharma Inc. is a very active stock that recorded a trading volume that is more than 22.41% of the average daily trading volume on Monday. The stock’s trading volume on Monday was 1636730, which is more than 22.41 of the total average daily trading volume of 1.27 million.
PDL BioPharma Inc. (NASDAQ:PDLI) 2020 Performance Impressive
The increase in PDLI’s stock price on Monday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of PDLI currently stands at $3.47, which is higher than the current trading price of the stock by 10.95%. However, PDLI’s current trading price is -80.7% lower than the 52-week low price of $1.71. In terms of trading volume, PDL BioPharma Inc. currently experienced healthy participation during the last trading session. 1636730 shares of PDL BioPharma Inc. were traded on the stock exchange on Monday, which is more than 22.41% of the 1.27 million average trading volume of the stock.
The performance of the stock has been positive over the past year. PDLI’s performance over the past one year has seen it surge by 24.49%, while the stock has gone up by 7.58% in the last six months. The quarterly performance of PDLI currently stands at 38.89%, and it is down by -6.08% in the last month. The only negative figure was from the weekly performance, which currently reads -4.63%. At the time of writing PDLI’s report, the company has a total market cap of $372.53M, making it one of the largest publicly-traded companies in the world.PDL BioPharma Inc. also has over 75 employees all over the world.
PDLI Insider Activities
For PDL BioPharma Inc., insiders hold 80.30% of all company shares. The insider transactions over the past six months are down by -2,838.50%. During that period, insiders bought 2,150,466 shares in 5 transactions. In that same period, insiders sold 754,993 of their shares in 2 transactions. After these transactions, insiders at PDL BioPharma Inc. now hold 4.14M shares, which is over 83.92% of the total company stocks. Institutional investors currently hold a large chunk of the PDLI shares, as they control 3.55% of the company’s total stock.
PDLI Fundamental Analysis
For PDL BioPharma Inc., the stock’s diluted earnings per share (EPS) stands at -0.79. In the coming year, analysts expect the EPS to be -0.06. The EPS growth will up over the next five years to 14.00% after plunging by -18.30% in the previous five years. In terms of revenue, PDL BioPharma Inc.’s quarterly sales (YOY) is growing at 0.10, which is higher than the average annual revenue of -18.30% over the past half a decade.
The Return on Investment (ROI) on PDL BioPharma Inc.’s stock currently stands at -17.00%. The gross margin of the company is 2.50%.
PDLI Analysts Prediction
The RBC Capital Mkts has a Sector Perform rating for PDL BioPharma Inc., predicting the stock price to stay between $5 and $4. Another analyst that has a Sector Perform rating for PDLI is RBC Capital Mkts, which set a price target of between $6 and $5. RBC Capital Mkts reiterate their Sector Perform position on the stock ($7 and $6) and RBC Capital Mkts reiterate their Sector Perform position on the stock ($8 and $7).
Analysts at RBC Capital Mkts believe that PDLI is Outperform, and they have a price target of between $6 and $6.
At the moment, PDL BioPharma Inc.’s Total Debt to Equity ratio stands at 0.02, and they have a long-term Debt to Equity ratio of 0.02.
PDLI Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of PDLI currently stands at -5.18%, while the SMA50 is 3.75%. The biggest one is the SMA200, which is currently reading 19.69% ahead of Monday’s trading session. The Relative Strength Index of this stock is 47.47.